# The Medicines (Products for Human Use-Fees) Regulations 2008, Paragraph 7: Authorisation for a national homoeopathic product


(1) In connection with an application for a marketing authorization for a national homoeopathic product prepared from not more than 5 homoeopathic stocks, the fee payable under regulation 12(1)(a) is the amount set out in Column (2) in the Table below opposite the description in Column (1) appropriate to that application.
(2) In connection with any other application for a marketing authorization for a national homoeopathic product, the fee payable under regulation 12(1)(a) shall be the amount set out in Column (3) in the Table below opposite the description in Column (1) appropriate to that application.
(3) This paragraph does not apply to an application which is a mutual recognition procedure incoming application or a decentralised procedure application.
Column (1)
Column (2)
Column (3)
Description of application
Fees for applications in respect of products prepared from not more than 5 homoeopathic stocks
Fees for other applications
1. An application in respect of a product which is both prepared solely from repeat stocks and is of a repeat formulation
£531
£753
2. An application in respect of a product which is either—
£832
£1,044
(a)
prepared solely from repeat stocks; or
(b)
is of a repeat formulation
3. Any other application
£1,120
£1,350
(4) Each reference in sub-paragraphs (5) to (7) to an amount payable under sub-paragraph (1) or (2) in respect of an application refers to the amount payable under that sub-paragraph in respect of an application of the kind in question.
(5) Where an application relates to a national homoeopathic product which is manufactured using a method of sterilisation—
(a) not used in the manufacture of a medicinal product in respect of which a marketing authorization (other than a product licence of right), a certificate of registration or a traditional herbal registration has previously been granted; and
(b) not referred to in the European Pharmacopoeia or any national pharmacopoeia of a member State,
an amount of £2,216 is payable in addition to the amount payable under sub-paragraph (1) or (2) in respect of that application.
(6) Where an application relates to a national homoeopathic product which contains one or more new excipients, an amount of £7,393 is payable in addition to the amount payable under sub-paragraph (1) or (2) in respect of that application.
(7) Where an application relates to a national homoeopathic product which contains one or more TSE risk ingredients or excipients from a new source, an amount of £653 is payable in addition to the amount payable under sub-paragraph (1) or (2) in respect of that application.
(8) In this paragraph—
“formulation” does not include the formulation of a homoeopathic stock;
“homoeopathic marketing authorization” means a marketing authorization granted by the licensing authority in respect of a national homoeopathic medicinal product;
“identical” means—
(a) in relation to the formulation of the product, identical as regards the requirements in respect of composition, preparation and testing; and
(b) in relation to a homoeopathic stock, identical as regards the source, composition and preparation of the stock and the test which it is required to undergo;
“product” includes a series of products each of which is prepared from identical homoeopathic stocks;
“repeat formulation” means—
(a) the formulation of a product which is identical to the formulation of another product—
(i) in respect of which the applicant holds a certificate of registration or a homoeopathic marketing authorization, or
(ii) to which the applicant has, by the holder of the certificate of registration or the homoeopathic marketing authorization which relates to it, been authorised in writing to make reference for the purposes of this application; or
(b) where more than one application is made by the same applicant on the same occasion in respect of products of identical formulations, for the purposes of the second and any subsequent of those applications which the licensing authority considers, the formulation of the product to which the first of those applications which is considered by the licensing authority relates; and
“repeat stock” means—
(a) a homoeopathic stock which is identical to another homoeopathic stock which is used in the preparation of a product—
(i) in respect of which the applicant holds a certificate of registration or a homoeopathic marketing authorization, or
(ii) in respect of which another person holds a certificate of registration or a homoeopathic marketing authorization to which, for the purposes of his application, the applicant has been authorised in writing to make reference by the person (or, if more than one, each of the persons) who supplied information to the licensing authority in connection with the application for the marketing authorization which relates to that product.

---
Source: https://www.legislation.gov.uk/uksi/2008/552/schedule/1/paragraph/7 (the official version)
Page: https://openlegislation.uk/medicines-products-for-human-use-fees-regulations-2008/schedule-1/paragraph-7
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.